Pharmaceutical Research & Manufacturers Association (PReMA) is pleased to announce its Code of Practice, 9th Edition, 2012. The enhancement of the Association’s code coincides with the 2012 revised Code of Practice of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA Code), which expands the scope of the longstanding marketing code of conduct for members. The 2012 revision of the IFPMA Code has expanded to cover topics beyond marketing practices to cover additional interactions with healthcare professionals, medical institutions and patient organizations. The revised IFPMA Code goes into effect this month. As a member of the IFPMA, PReMA is committed to ensuring that its national Code is aligned with the international IFPMA Code.
PReMA further supports the APEC Mexico City Principles for Voluntary Codes of Business Ethics in the Biopharmaceutical Sector. The Mexico City Principles are consistent with the revised IFPMA Code and were adopted in 2011 at the Leaders Meeting of the Asia Pacific Economic Cooperation (APEC) forum held in Honolulu, Hawaii. A work program is now underway to help all of the APEC region’s pharmaceutical associations, medical societies and governments develop and implement codes of conduct based upon these Principles, which reflects an active partnership between governments, small and large industry and the medical community. A workshop to help develop codes of conduct based upon the principles was held in Taipei, Taiwan, in July 2012, with a view to helping associations without codes, or those with codes that do not meet the standards of the APEC Principles, to draft and implement codes. In 2013, Indonesia will host a broad stakeholders educational session targeted at governments and medical societies and Malaysia will host a follow on train-the-trainers session. PReMA fully supports these efforts and commits to working with the government to encourage compliance by all stakeholders in this important area over the coming years.
Representing the research-based pharmaceutical industry in Thailand, PReMA is committed to the improvement of public health through the research, development, production, marketing and safety surveillance of new medicines of reliable quality, in accordance with internationally defined standards of good practice. As part of its commitment to health, the industry recognizes it has an obligation and responsibility to provide accurate information about its products to healthcare providers to ensure the appropriate use of medicines.
In line with the IFPMA Code and APEC Principles, PReMA requires that promotional activities are consistent with high ethical standards and that information is supplied to help healthcare professionals to provide the best care to patients. Information provided must be truthful and scientifically accurate, and it must also conform to all relevant laws and regulations. Claims for therapeutic indications and conditions of use must be based on valid scientific evidence, have received approval of relevant regulatory authorities, and include clear statements with respect to side effects, contra-indications and precautions.
High standards of ethical behavior should apply to the promotion of pharmaceutical products in all countries, regardless of the level of development of their economic and health care systems or the size of their firms. In recognition of this fact, the APEC Ministers responsible for Small and Medium Enterprises initiated work in this area as one critical to the health of their respective national industries, economies and patients. PReMA calls upon all other national and international actors in the healthcare field to operate under similar ethical guidelines for the benefit of patients.
For media information, please contact
Total Quality PR (TQPR) Thailand Co. Ltd.,
Maetavarin Maneekulpan/ Tantida Tammakhupat
Tel: 02-260-5820 ext. 115/ 120